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Background: We investigated the frequency of RAVs among patients failing to achieve SVR in two clinical
trials. We also investigated the impact of interferon responsiveness on RAVs and speciﬁc baseline RAVs
relationship with boceprevir treatment failure.
Methods: Data are from 1020 patients enrolled into either SPRINT-2 or RESPOND-2; patients received a
4-week PR lead-in prior to receiving boceprevir or placebo. RAVs were analyzed via population-based
sequence analysis of the NS3 protease gene (success rate of 490% at a virus level of ≥10,000 IU/mL)
Results: The high SVR rate in patients who received boceprevir resulted in a low rate of RAVs; 7% was
detected at baseline in all patients, which rose to 15% after treatment. However, RAVs were detected in
53% of patients that failed to achieve SVR, which declined to 22.8% 6–14 months following cessation of
boceprevir therapy. Baseline RAVs alone were not predictive of virologic outcome; poor interferon
responsiveness was highly predictive of non-SVR. RAVs were more frequently detected in poor interferon
responders.
Conclusions: We detected no association between the presence of baseline amino acid variants at
boceprevir resistance-associated loci and outcome in the context of good IFN response.
& 2013 Elsevier Inc. All rights reserved.Introduction
Up to 2–3% of the worlds’ population is chronically infected with
Hepatitis C Virus (HCV) and three to four million people globally
become newly infected each year (Shepard et al., 2005). In developed
countries, HCV related cirrhosis is one of the most common reasons
for liver transplantation. It is estimated that 20% of persons with
untreated chronic HCV infections will progress to cirrhosis and 15% of
individuals with cirrhosis will develop hepatocellular carcinoma
within 5 years (Davis et al., 2010). While peginterferon and ribavirin
(PR) therapy of HCV infection allows for a sustained virologic
response (SVR) in about 40–50% of genotype 1-infected patients
and in 80–90% of those infected with genotypes 2 or 3 (Zeuzem,
2008; McHutchison et al., 2009), other treatments are available. The
new standard of care for genotype 1 is combination therapy with
PR in combination with boceprevir or telaprevir.ll rights reserved.
. Barnard).Treatment of HCV infection has historically been based on host-
directed therapies that stimulate the immune system. However,
recent advances in the ﬁeld have enabled the development of
numerous direct-acting antiviral agents that directly inhibit essen-
tial HCV proteins required for viral replication (McGovern et al.,
2008). Boceprevir is a peptidomimetic ketoamide protease inhi-
bitor that binds reversibly to the HCV non-structural protein 3
(NS3) active site (Berman and Boceprevir, 2009; Mederacke et al.,
2009). Boceprevir has demonstrated antiviral activity in vitro (e.g.,
HCV replicon models), as monotherapy in Phase 1 studies, and in
multiple Phase 2 trials in combination with the standard of care of
PR (Malcolm et al., 2006; Sarrazin et al., 2007; Schiff et al., 2008;
Kwo et al., 2010) Boceprevir has also been studied in Phase
3 clinical trials in treatment naïve (SPRINT-2) (Poordad et al.,
2011) and previously non-responsive (RESPOND-2) (Bacon et al.,
2011) HCV infected patients.
While the discovery and development of direct acting antiviral
therapies against HCV has advanced treatment signiﬁcantly, the
use of these new agents is not without potential challenges. As
with HIV, the potential for rapid emergence of drug-resistant
R.J.O. Barnard et al. / Virology 444 (2013) 329–336330variants of HCV is of major concern. HCV variants arise from a
combination of the inherent poor ﬁdelity (Castro et al., 2005) of
the RNA dependent RNA polymerase and the high rate of viral
replication (Neumann et al., 1998; Perelson et al., 1996). Amino
acid changes in the HCV NS3 protease domain sequence that
confer reduced susceptibility to boceprevir (also termed RAVs;
resistance associated amino acid variants) have been characterized
identiﬁed both in replicons selected for boceprevir resistance
in vitro and in viruses isolated in vivo from HCV-infected patients
failing to achieve SVR with a boceprevir regimen (Tong et al., 2006,
2008; Curry et al., 2008; Susser et al., 2009).
In this report we investigate the frequency of baseline and post-
baseline RAVs among patients failing to achieve SVR in SPRINT-2 and
RESPOND-2, the registration trials for boceprevir. In addition, we
investigate the impact of interferon responsiveness on RAV frequency
at failure as well as whether speciﬁc baseline RAVs were more
commonly associated with boceprevir treatment failure.
Results
Sample accounting
A total of 1020 patients received boceprevir in two phase three
studies; SPRINT-2 (Poordad et al., 2011) (PR treatment naïve
patients) and RESPOND-2 (Bacon et al., 2011) (patients previously
treated with PR). To analyze boceprevir resistance, the NS3/4a
region of the HCV genome was ampliﬁed from patient plasma
samples using standard reverse transcriptase/PCR techniques and
subjected to population sequence analysis. Of the 1020 patients
enrolled in the SPRINT-2 and RESPOND-2 studies that received
boceprevir, baseline samples from 1013 patients were sequencedFig. 1. Combined resistance sequencing summ
Table 1
Non-SVR patients with post-baseline RAVs detected.
Patient Category Total
Non-SVR 343
Incomplete virological response 61
Viral breakthrough 26
Relapse 79
Nonresponder/Futility 79
Nonresponder/Non-futility 98and data were obtained for 980/1013 subjects (Fig. 1). Sequencing
failed for 33 patients and 7/1020 patients did not have adequate
baseline samples (available prior to any treatment) for resistance
testing. Of the 343 patients who did not achieve SVR, 41/343
patients did not have post-baseline samples available or did not
have samples with an adequate viral load for resistance analysis.
Viruses from 302/343 patients were sequenced and resistance data
was available for 295 of these subjects (Fig. 1).
Sequence analysis from post-baseline samples
The generally high overall SVR rate in patients who received
boceprevir in both treatment naïve (SPRINT-2; 63–66%) and
treatment experienced (RESPOND-2; 59–66%) resulted in an over-
all low rate of RAVs. Overall, 15% (157/1020) of all patients treated
with boceprevir had post-baseline RAVs detected (Fig. 2A). One
patient that achieved SVR had RAVs (T54S) detected at TW8 of the
study. Of the patients not achieving SVR with available resistance
data (n¼295), 53% (156/295) had post-baseline RAVs detected
(Table 1). RAVs were more frequently detected among genotype 1a
non-SVR patients (55%; 118/214) compared to genotype 1b
infected patients (47%; 38/81) (Fig. 2B). In addition SVR rates were
also lower in genotype 1a patients (63%) compared to genotype 1b
patients (73%) (data not shown). The difference in SVR rates
among genotype 1a and 1b patients was similar in the SPRINT-2
(11.2%) and RESPOND-2 (9.2%), respectively.
Among genotype 1a infected patients, the RAVs most fre-
quently detected at virologic failure were V36M (60%), R155K
(67%) and T54S (19%) (Fig. 2C). In contrast, the RAVs most
commonly detected in patients with genotype 1b virus were
T54A (42%), T54S (37%), V55A (24%), A156S (26%) and V170Aary for patients that received boceprevir.
Patients with RAVs
detected/patients data available
% Patients with
RAVs detected
156/295 53%
54/59 92%
18/24 75%
33/78 42%
34/71 48%
17/63 27%
Fig. 2. (A) Post-baseline RAVs identiﬁed in patients that received boceprevir, (B) frequency of RAVs in non-SVR patients by genotype, and (C) frequency and distribution of
post-baseline RAVs by genotype.
R.J.O. Barnard et al. / Virology 444 (2013) 329–336 331(32%) (Fig. 2C). The remaining RAVs at positions V36, T54, V55,
R155, A156, V158 and D168 in both genotypes were detected at
frequencies o10% of total patients with post-baseline RAVs
(Fig. 2C).
Post-baseline RAVs were more frequently detected among non-
SVR patients that experienced virologic breakthrough during the
boceprevir/PR dosing period, i.e. during the period of maximum
boceprevir-exposure. Overall, 92% (54/59) of patients that experi-
enced IVR, 75% of BT subjects (18/24) and 48% of NRFUT patients
(34/71) had viruses with RAVs detected post-baseline (Table 1).
RAVs were detected less frequently among RL patients (32/78, 41%)that experienced virologic failure after cessation of Boceprevir/PR
therapy. RAVs were only detected in 27% (17/63) of NROther
patients that discontinued boceprevir/PR therapy for reasons other
than futility (Table 1).
RAVs are rapidly selected during short-term monotherapy
dosing studies with ﬁrst generation HCV protease inhibitors.
Therefore, in order to maintain viral suppression of resistant
variants, boceprevir is administered in combination with pegin-
terferon/ribavirin. To investigate the impact of interferon respon-
siveness on the development of RAVs, interferon response was
assessed based on the decrease in HCV viral load at the end of the
R.J.O. Barnard et al. / Virology 444 (2013) 329–3363324-week PR lead-in or by assessment of host IL-28b genotype
(Sarrazin et al., 2007; Kieffer et al., 2007).
All patients in the SPRINT-2 and RESPOND-2 studies received
PR alone for 4-weeks, prior to boceprevir/PR dosing, allowing an
on-study assessment of interferon responsiveness in patients.
Interferon responses in patients were classiﬁed based on the
decline in HCV RNA at the end of the week 4 PR lead in (TW4).
Patients that experienced a o1 log10 decline in HCV RNA levels at
TW4 were classiﬁed as poor interferon responders and patients20
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Fig. 3. (A) RAVs detected in non-SVR patients by interferon responsiveness at TW4
and (B) RAVs detected in non-SVR patients by IL-28b genotype. CC, IFN responsive;
CT, less IFN responsive; TT, not IFN responsive.
Table 2
RAVs detected at baseline.
Genotype Subjects Samples
sequenced
Samples
sequenced
and RAVs
detected,
n/N (%)a
Number of subjects with samples seq
V36I V36L V36M Q41
All Subjects 1020 980 66/980(7) 2/66(3) 14/66(21) 2/66(3) 4/6
1a 656 628 53/628(8) 1/53(2) 13/53(25) 2/53(4) 2/5
1b 359 352 13/352(4) 1/13(8) 1/13 (8) 0/13(0) 2/13
RAV=resistance associated amino acid variants.
Two patients had an indeterminate genotype 1 subtype and 3 patients infected with no
a Number of subjects with samples sequenced and RAVs detected/total number of s
b Number of subjects with samples sequenced and RAVs detected for each RAV/total
more than one RAV and appear in the more than one RAV count.with a decline in HCV RNA of ≥1 log10 at TW4 were classiﬁed as
interferon responders.
Poorly interferon responsive non-SVR patients were more
likely to fail treatment with detectable RAVs than those who were
classiﬁed as IFN responders (Fig. 3A); 68% (115/169) of poorly
interferon responsive patients had detectable RAVs, compared to
31% of interferon responders (41/128) (Fig. 3A). The higher
frequency of RAVs detected among poorly interferon responsive
patients is partly explained by the higher proportion of patients
that experienced virologic failure during boceprevir dosing
(BT, IVR and NRFut) 63% (118/186) compared to interferon respon-
sive patients 31% (47/149) (Supplementary Table S1).
Genome-wide association studies have identiﬁed genetic
variations near the IL-28b gene, encoding interferon-λ-3, that
can inform on the interferon/ribavirin responsiveness of patients
(Ge et al., 2009). Interferon responsiveness has been linked to a
single nucleotide polymorphism in the IL-28b gene (http://www.
ncbi.nlm.nih.gov/pubmed/19684573). Approximately 60% of
patients in the SPRINT-2 and RESPOND-2 studies consented to
have IL-28b genotypic testing, allowing another independent
measure of the association of RAVs to interferon responsiveness.
Patients with a ‘CC’ rs12979860 IL-28b genotype have been
associated with favorable IFN responsiveness, whereas patients
with ‘TC' or ‘TT’ rs12979860 genotypes have less favorable inter-
feron responsiveness. Consistent with this, SVR rates among
‘CC’ patients was higher (80%) than that of ‘TC’ (68%) or ‘TT’
patients (59%) (Poordad et al., 2012). The data from this ana-
lysis corroborate previous results indicating a higher frequency of
RAVs in patients who are poorly IFN responsive (Fig. 3B). Roughly
29% of ‘CC’ IFN responsive patients had a post-baseline RAV
detected. However RAVs were detected more frequently among
poorly IFN-responsive patients, with 51% of ‘TC’ and 62% of ‘TT’
poorly IFN-responsive subjects harboring post-baseline RAVs,
respectively.
Consistent with reported lower responsiveness to interferon
among black patients, 59% of black patients had post-baseline
RAVs detected, compared to 45% for non-black patients (Supple-
mentary Fig. S1).
Baseline RAVs
Due to the poor ﬁdelity of the HCV RNA-dependent RNA
polymerase (NS5B), it is likely that many boceprevir RAVs pre-
exist prior to initiation of therapy (Colson et al., 2008; Bartels et al.,
2008). Baseline sequence data were available for 980/1020
patients; 628/656 patients with genotype 1a virus, 352/359 with
genotype 1b virus (Table 2). Amino acid variants were detected at
one or more of the 11 boceprevir resistance-associated loci (RAVs)uenced and RAVs detected, n/N (%)b
H T54A T54S V55A V55I R155K V170M M175L
6(6) 1/66(2) 18/66(27) 22/66(33) 15/66(23) 1/66(2) 2/66(3) 1/66(2)
3(4) 1/53(2) 14/53(26) 20/53(38) 13/53(25) 1/53(2) 0/53(0) 0/53(0)
(15) 0/13(0) 4/13(31) 2/13(15) 2/13(15) 0/13(0) 2/13(15) 1/13 (8)
n-genotype 1 viruses were excluded from the above analysis.
ubjects with samples sequenced.
number of subjects with samples sequenced and RAVs detected. Subjects may have
Table 3
SVR rates by treatment week 4 response among patients with or without baseline RAVs detected.
Totala SVR (%)
Interferon respondersb Poor interferon respondersc
Patient (n) SVR (%) Patients (n) SVR (%)
Patients without baseline RAVs 902 67% 648 79% 254 34%
Patients with baseline RAVs 64 65% 51 76% 13 23%
V36M, R155K, T54S/A and V55A 43 65% 36 78% 7 0%
Other baseline RAVs (V36L, V36I, Q41H, V55I, V170M, M175L) 21 67% 15 73% 6 50%
a Total with Week 4 vial load available (treatment week 4 data not available for 12 patients without baseline RAVs and 2 with baseline RAVs).
b Patients with ≥1 log10 decrease in viral load at treatment week 4.
c Patients with o1 log10 decrease in viral load at treatment week 4. SVR, sustained virologic response; RAVs, resistance associated amino acid variants.
Table 4
454-Sequence analysis quantiﬁcation of RAVs during the 4-week lead-in.
Patient HCV RNA baseline
(IU/ml)
HCV RNA treatment Week 4
(IU/ml)
Log10 decline in HCV
RNA
Treatment
response
RAV
(Codon)
Baseline
RAV %
Treatment
Week 4%
% Change from
baseline
1 11,700,000 5,030,000 0.37 Poor IFN
responder
V55A
(GCC)
97.92% 97.65% 0.27%
2 20,900,000 3,380,000 0.79 Poor IFN
responder
V55A
(GCC)
93.17% 96.16% 2.99%
V55A
(GCT)
6.43% 3.75% 2.68%
3 4,030,000 3,660,000 0.04 Poor IFN
responder
T54A
(GCC)
64.62% 57.32% 7.30%
T54A
(GCT)
34.92% 41.53% 6.61%
4 3,810,000 449,000 0.93 Poor IFN
responder
V55A
(GCC)
83.38% 81.13% 2.25%
V55A
(GCT)
15.84% 18.33% 2.49%
5 399,000 6900 1.76 IFN responder V55A
(GCT)
99.20% 98.80% 0.40%
6 2,450,000 175,000 1.15 IFN responder T54S
(TCC)
99.48% 99.68% 0.20%
R.J.O. Barnard et al. / Virology 444 (2013) 329–336 333in 7% (66/977) of patients with samples sequenced; 53/628 (8%)
patients with genotype 1a virus and 13/352 (4%) patients with
genotype 1b virus.
SVR rates among patients with baseline RAVs detected (65%,
43/66) were similar to those without baseline RAVs detect-
able (67%, 599/902) (Table 3). Overall, baseline RAVs alone were
not predictive of virologic outcome.
Of the 66 boceprevir-treated patients with RAVs detected at
baseline, 43 had V36M, R155K, T54A/S, and/or V55A (Table 3)
which were frequently detected in non-SVR patients at virologic
failure (Supplementary Fig. S2). 21 patients at baseline had
infrequent post-baseline variants V36I/L, Q41H, V55I, V170M
and/or M175L. These 5 variants were not commonly detected in
virologic failure samples from non-SVR patients; however, these
variants were shown to have resistance to boceprevir in vitro (data
not shown). Of the 43 patients who had V36M, R155K, T54A/S,
and/or V55A, 36 were interferon responsive and 7 were poorly
interferon responsive (as deﬁned at TW4). The SVR rate among
interferon responsive patients with V36M, R155K, T54A/S, and/or
V55A RAVs present at baseline (78%; 28/36) was similar to the SVR
rate among interferon responsive patients with V36I/L, Q41H,
V55I, V170M and/or M175L at baseline (73%; 11/15) or those
without baseline RAVs detected (79%, 513/648) (Table 3). In
contrast, the SVR rate among poorly interferon responsive patients
with RAVs V36M, R155K, T54A/S, and/or V55A was 0% (0/7),
compared to SVR rates of 50% (3/6) among poorly interferon
responsive patients with baseline RAVs V36I/L, Q41H, V55I,
V170M and/or M175L or 34% (86/254) with no baseline RAVs
detected (Table 3). Although the numbers of patients are small, the
combination of poor interferon responsiveness and V36M, R155K,
T54A/S, and/or V55A RAVs at baseline appeared to correspondwith a poor treatment outcome. The numbers of patients with a
combination of poor interferon responsiveness and baseline
V36M, R155K, T54A/S, and/or V55A RAVs represented 1%
(7/1020) of patients treated with boceprevir. It is important to
remember that these data are from population sequencing and
therefore RAVs present in low number (o20%) may not be
detected due to the relatively low assay sensitivity.
RAVs detected after the 4-week PR lead-in
As RAVs do not confer resistance to PEG IFN or ribavirin, one of
the putative beneﬁts of the 4-week PR lead in would be to reduce
the viral burden of pre-existing RAVs, prior to the addition of
boceprevir to the combination therapy. To test this hypothesis,
RAVs were quantiﬁed by 454-sequencing at baseline and after the
4-week lead-in period. As viruses that harbor RAVs often make up
a very minor part of the circulating population, six patients were
selected that had viruses with RAVs detected at baseline by
population sequencing. This guaranteed that a signiﬁcant propor-
tion of the circulating viruses would harbor RAVs, allowing for the
accurate quantiﬁcation of RAVs in the subsequent pyrosequence
analysis. Four of the six patients experienced o1 log10 decline in
HCV RNA levels by TW4 and were classiﬁed as poor-interferon
responders. Two patients experienced 41 log10 decline in HCV
RNA levels and were classiﬁed as interferon responders (Table 4).
Patients were selected with high viral loads to mitigate re-
sampling errors in the pyrosequence analysis.
RAVs identiﬁed by population sequencing at baseline were
detected in 495% of all viral sequences in the pyrosequence
analysis. These included V55A, T54A or T54S. In three patients,
RAVs were encoded by two different codons, indicating the
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that existed prior to treatment (Table 4). As all six patients had
high viral loads (4400,000 IU/ml) at baseline, these viral variants
did not appear to have impaired replication capacity. The fre-
quency with which these RAVS were detected in the overall
population at baseline and at treatment week 4 is listed in
Table 4. In all six patients, the frequency of viruses harboring
RAVs at treatment week 4 was similar to the frequencies identiﬁed
at baseline.
The viral load of viruses harboring each RAV can be estimated
at each time point by multiplying the frequency of each RAV by the
total viral load. As the viral load declined during the 4 week PR
lead-in in all six patients, the viral load of all RAVs also declined
from their baseline values (Table 4). Importantly, boceprevir RAVs
at other loci (positions 36, 155, 156, 170 or 175) were not detected
at the end of the 4 week P/R lead-in phase, indicating that there
was no signiﬁcant enrichment of other RAVs.
RAVs were present in over 95% of the sequences at baseline and
remained at these levels at the end of the 4 week lead-in phase.
RAVs declined in viral load in all six patients during the 4-week
lead in, suggesting that viruses that harbor these RAVs were
sensitive to P/R therapy and that the viral burden of RAVs declines
during the lead-in phase.RAVs detected during follow-up
Among non-SVR patients, resistance sequencing was per-
formed at two time points; virologic failure and at what would
have been the SVR24 time point (i.e. at both the virologic failure
time point and the end of study time point). An assessment of the
longevity of RAVs during follow-up could not be made as patients
discontinued all treatment at virologic failure. As patients experi-
enced virologic failure at different times; the length of follow-up
differed, ranging from 6 to 14 months with a median of 10 months.
Data were available at both these time points for 127/156 of the
non-SVR patients with detectable RAVs. Fig. 4 shows the frequency
of patients that experienced virologic failure with speciﬁc RAVs
that were no longer detected at the end of the second ‘end of
study’ time point. The incidence of RAVs at the second time point
differed among different variants. RAVs T54A and A156S declined
to undetectability in 483% of genotype 1a and 1b infected
patients. However, only 67–69% of patients with T54S or R155K
no longer had these RAVs detected at the second time point. There
was little difference in the speed of decline based on the genotype
(differences with V55A were due to small numbers of this variant
detected). Given the low sensitivity of population sequencing92
69
100
90
77
100
67
50
68
83
0 20 40 60 80 100 120
V36M
T54A
T54S
V55A
R155K
A156S
Patients with no detectable RAVs by population sequencing, %
Gen1A
Gen1B
Fig. 4. Most common RAVsn: detectability declines during 6–14 month follow-up.
nIn non-SVR patients with detectable RAVs at treatment failure in SPRINT-2 and
RESPOND-2 (as of latest follow-up time point [range 6–14 months]).(detection limit 10–20% of minor variants), it is possible that
RAVs not detected at the second time point are still present.
Population sequence data were compared for 506 subjects in
the response guided therapy arms and 514 subjects in the
boceprevir/P/R 48 week arms of SPRINT-2 and RESPOND-2
(Supplementary Table S2). Post-baseline sequence data were
available for 158/506 patients in the response guided therapy
arms and 142/514 patients in boceprevir/PR 48 week arms. The
percentages of patients with samples sequenced and post-baseline
RAVs were identical between the two arms (52%, 82/158 and 52%,
74/142). The most common RAVs detected in both arms were
V36M, R155K, T54A, and T54S.Discussion
In the current report we investigated the frequency of baseline
and post-baseline RAVs among non-SVR patients enrolled in
SPRINT-2 and RESPOND-2 by population sequencing. Given the
high error rate of the NS5B RNA-dependent RNA polymerase and
the high rate of HCV replication, it has been hypothesized that all
single- and double-amino acid variants that can lead to a decrease
susceptibility to direct acting antiviral agents pre-exist in the viral
population prior to the initiation of therapy (Rong et al., 2010).
Consistent with this hypothesis, RAVs were detected in 7% of
patients (by population sequencing), prior to the treatment with
boceprevir (Supplementary Fig. S2). It is possible that many RAVs
exist prior to the treatment below the level of detection of
population sequence analysis (detection limit 20% of circulating
viruses). RAVs with a low replicative capacity/ﬁtness might not be
detected using this technology; therefore, studies that seek to
identify these variants at baseline using deep-sequence technol-
ogy are ongoing. Although RAVs were detected by population
sequence analysis, in most cases the presence of these variants did
not preclude the ability of patients to achieve SVR. As viruses
harboring boceprevir RAVs are sensitive to PR treatment (Table 4)
the responsiveness of patients to interferon likely plays a key role
in the clearance of pre-existing variants which harbor resistance to
boceprevir. This would be consistent with the observation that
patients who had baseline RAVs commonly associated with
virologic failure (V36M, T54A/S, V55A and R155K) and who were
also poor interferon responders all failed to achieve SVR. However,
this accounts for only a small number of the non-SVR patients and
given the heterogeneous responses of patients to PR, the ability to
clear viruses containing RAVs will differ making it hard to estab-
lish a viral load threshold for RAVs at baseline that could aid in
predicting the treatment outcome.
In a recent telaprevir publication based on phase III data, resistance
associated variants were observed in 77% (299/388) of patients who
did not achieve SVR (Sullivan et al., 2013). This compares to 47% in the
current study (143/300). Telaprevir RAVs occurred more commonly in
subtype 1a (86%; 232/269) than subtype 1b infections (56%; 67/119),
compared to the current study where boceprevir RAVs were found in
55% (118/214) and 47% (38/81) of genotype 1a and 1b infected non-
SVR patients, respectively.
RAVs detected in both the telaprevir study and the current
study were similar. The majority (~91%) of 1a-infected patients in
the telaprevir study had resistant variants carrying V36M (12%),
R155K (22%), or the combination of V36M and R155K (56%). The
majority (84%) of 1b-infected patients in the telaprevir study had
V36A (28%), T54A (39%), or A156S/T (22%). In the current study the
RAVs most frequently detected at virologic failure among genotype
1a infected patients were V36M (60%), R155K (67%) and T54S
(19%). RAVs most commonly detected in patients with genotype 1b
virus in the current study were T54A (42%), T54S (37%), V55A
(24%), A156S (26%) and V170A (32%).
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ment of RAVs. The incidence in patients poorly responsive (o1
log10 decrease in HCV-RNA at TW 4 from baseline) to IFN was
twofold higher than in those with good response to IFN (≥1 log10
decrease in HCV-RNA at TW 4 from baseline). Among all subjects
with samples analyzed, 68% of poorly IFN responsive subjects had
RAVs compared to 32% of those with better IFN response. This
ﬁnding is partly explained by the fact that poorly interferon
responsive patients were more likely to experience virologic fail-
ure during dosing than interferon responsive patients (Table 3).
This is consistent with data obtained when patient IL-28b geno-
type is used as a marker of interferon responsiveness (Fig. 3B).
Further analysis by race category demonstrated that Black
patients had a higher percentage of RAVs detected post-baseline
compared to non-black patients. Detection of RAVs after the
initiation of treatment in Black patients was similar for both
boceprevir/PR treatment strategies (response guided therapy vs.
48 weeks). This is likely due to the poorer responsiveness to
interferon in these patients (Brau et al., 2006).
The differences in the detected RAVs between genotype 1a and
1b are likely to at least in part be inﬂuenced by the differences in
genetic barrier of the more common Gt1a and Gt1b RAVs. Variants
V36M or R155K require only a single nucleotide change in
genotype 1a viruses, but require two nucleotide changes in
genotype 1b viruses. Conversely, V170A variants require only a
single nucleotide change in genotype 1b viruses but two nucleo-
tides in genotype 1a virions.
Following treatment, RAVs frequently declined to below the
level of detection in population sequence assays, reﬂecting a
decrease in abundance of viruses harboring RAVs over time in
patients. The number of patients with RAVs detected at the second
time point differed for the different RAVs, likely reﬂecting differ-
ences in the viral ﬁtness of each RAV. Indeed, the in vitro ﬁtness of
RAVs that declined most rapidly (A156T) have been demonstrated
to have a lower replicative capacity than variants such as R155K
that declined at a lower rate in vivo (Shimakami et al., 2011). The
clinical signiﬁcance of these ﬁndings on the re-treatment of
patients with HCV protease inhibitors with overlapping resistance
proﬁles remains to be determined.
In conclusion, it is important to note that the potential
presence of baseline RAVs should not preclude therapy with
PEG/RBV and boceprevir. The likelihood of developing RAVs relates
to PEG IFN responsiveness of the hepatitis C infected individual.
The use of lead-in as well as the determination of IL-28 B status
can help guide clinicians in assessing the risk for developing RAVs
when considering boceprevir based therapy.Methodology
Subjects
Data reported herein are from patients enrolled into either
SPRINT-2 or RESPOND-2 (the registration trials for boceprevir).
Detailed methodologies for both of these studies have been
published (Poordad et al., 2011; Bacon et al., 2011). For the
SPRINT-2 and RESPOND-2 Studies, HCV-RNA was quantiﬁed using
the Roche High Pure System/Cobas Taqman assay, v2.0 with an
overall limit of detection of 25 IU/ml. LOD by 95% hit rate Probit
analysis for genotype 1 isolates in plasma was 9.3 IU/ml. Brieﬂy,
both trials were double-blinded for boceprevir, and all patients
received a 4-week lead-in with PR prior to receiving either
boceprevir or placebo. The primary endpoint of each trial was
SVR, compared to the placebo control. In both SPRINT-2 and
RESPOND-2 clinical trials, non-SVR patients were categorized
based on the following 5 treatment responses; Breakthrough(BT; patients on treatment whose HCV-RNA became detectable
after having achieved an undetectable level of HCV-RNA), Incom-
plete Virologic Response (IVR; patients that experienced≥1
log10 IU/mL increase in HCV-RNA from nadir during treatment),
Relapsers (RL; patients that had undetectable HCV-RNA at the end
of treatment but subsequently had detectable HCV-RNA at end of
the 6 month follow-up period), Non-ResponderFutility (NRFut;
patients that had detectable HCV RNA at treatment week 12
(SPRINT-2) or week 24 (RESPOND-2) and met the futility disconti-
nuation rule) and Non-ResponderOther (NROther; patients that
discontinued for reasons other than meeting a futility rule, such
as the occurrence of an adverse event or withdrawal of consent).Study procedures
There were a total of 1058 patients randomized to receive
boceprevir in the SPRINT-2 (735 patients) and RESPOND-2 (324
patients) studies. However, 38/1058 of these patients (30 from
SPRINT-2 and 8 from RESPOND-2) discontinued the study during
the lead-in phase, prior to receiving a dose of study drug. There-
fore, 1020 patients received study drug in SPRINT-2 and RESPOND-
2 and were the focus of the resistance analysis. To detect RAVs
prior to study treatments in SPRINT-2 and RESPOND-2, plasma
samples were collected for NS3 sequence analysis in all patients
(n¼1020) at baseline (or from screening sample if day 1 was
missing). In addition, samples were taken at or near the time of
virologic failure in patients who did not achieve SVR during
SPRINT-2 or RESPOND-2 (n¼343). Population sequencing of the
entire NS3 region was performed by Janssen Diagnostics (NJ).Sequence analysis
In both the SPRINT-2 and RESPOND-2 clinical studies, sequence
analysis was performed on plasma samples obtained at the
following time points; at baseline (all patients), at treatment week
8 (if the viral load 41000 IU/ml), at virologic failure (all non-SVR
patients). For technical reasons, sequence analysis was performed
only on patient plasma samples with a viral load of 41000 IU/ml.
Plasma samples were evaluated by population sequencing and
analyzed to detect amino acid variants in the NS3/4A protease
known or suspected to be associated with reduced susceptibility to
boceprevir. The population sequence analysis was performed at
Janssen Diagnostics BVBA (Belgium). Where possible, the entire
NS3/4a region of the HCV genome was ampliﬁed for using
genotype-speciﬁc primers by nested RT-PCR. However, if ampli-
cons could not be generated for the full NS3/4a region, a smaller
amplicon encompassing just the NS3 region (amino acids 1–180 of
the HCV NS3 protease) was ampliﬁed. The NS3/4a or NS3 regions
were then subjected to population sequence analysis. The success
rate of the assay is 490% at a virus level of ≥10,000 IU/mL but
decreases with declining viral loads to approximately 71% success
rate at 1000 IU/mL.
Resistance analyses focused on 11 positions (“loci”) in the
amino acid sequence of the NS3/4A protease domain at which
substitutions (“RAVs”) had been identiﬁed and shown to confer
reduced susceptibility to boceprevir. The amino acids found at the
11 loci of NS3 in the genotype 1a strain H77 used in the analysis
were V36, Q41, F43, T54, V55, R155, A156, V158, D168, I/V170, and
L175. The amino acids found at the 11 loci of NS3 in the genotype
1b strain Con1 used in the analysis of samples with genotype 1b
were V36, Q41, F43, T54, V55, R155, A156, V158, D168, V170, and
M175. Samples with genotype 1a1b, genotype 1 (subtype not
speciﬁed) and non-1 genotypes were aligned to the genotype 1a
H77 reference sequence.
R.J.O. Barnard et al. / Virology 444 (2013) 329–336336Pyrosequencing
Pyrosequence analysis was performed by Jansen Diagnostics
(Belgium). Viral RNA was isolated from plasma samples collected
at baseline and treatment week 4 for the six patients enrolled in
the boceprevir phase 2/3 clinical studies. Amino acids 1–181 of the
HCV NS3 gene were ampliﬁed by two separate amplicons using
standard RT-PCR techniques and subjected to pyrosequence
analysis. Sequence analysis was performed using the Roche 454
Genome Sequencer FLX using titanium plates. Processing of the
raw sequence data was analyzed using the Roche 454 software
package (Sequencing System Software). GS Amplicon Variant
Analyzer (AVA) software (Roche) was used for mapping and
variant calling. No ﬁltering or trimming on Phred quality values
(QVs) was performed other than those dictated by the Roche
Software. Variants were determined at each codon (position 3)
using proprietary software developed by Janssen Infectious
Disease-Diagnostics.
The number of independent sequences for each HCV NS3 codon
varied for each amplicon, with 495% of codons being represented
by at least 1800 sequences and 475% represented by 5000
sequences. In order to separate real variants from sequencing
artifacts, codons had to be represented by 450 sequences,
according to manufacturer’s instructions. This led to a lower limit
of sensitivity of this assay that ranged from 0.13 to 10.92%,
depending on the number of independent sequences.Disclosures
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